Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: GlobeNewswire
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. “Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy,” said Talat Imran, Chief Executive Officer of Rani. “As we continue to expand our pipeline and evaluate new opportunities for the RaniPill® platform, Jesper will play a critical role in helping us prioritize the most impactful programs and align our strategy with areas of greatest clinical and market potential.
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics (RANI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Rani Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateGlobeNewswire
RANI
Earnings
- 3/26/26 - Miss
RANI
Sec Filings
- 3/27/26 - Form 3
- 3/27/26 - Form SCHEDULE
- 3/26/26 - Form S-8
- RANI's page on the SEC website